Read by QxMD icon Read

Bladder cancer, biomarkers

Chun-Wei Yang, Shu-Fang Wang, Xiang-Li Yang, Lin Wang, Lin Niu, Ji-Xiang Liu
One of the most common head and neck cancers is laryngeal squamous cell carcinoma (LSCC). LSCC exhibits high mortality rates and has a poor prognosis. The molecular mechanisms leading to the development and progression of LSCC are not entirely clear despite genetic and therapeutic advances and increased survival rates. In this study, a total of 116 differentially expressed genes (DEGs), including 11 upregulated genes and 105 downregulated genes, were screened from LSCC samples and compared with adjacent noncancerous...
February 2018: Medicine (Baltimore)
Qiao-Li Lv, Hui-Ting Zhu, Xiao-Hua Cheng, Hong-Mi Li, Hong-Hao Zhou, Shu-Hui Chen
Emerging studies show that dysregulated miRNAs are implicated in tumorigenesis and progression of various cancers. MiRNA-320c, an important member of miRNA-320 family, was characterized as a new candidate miRNA that suppressed the development of colorectal cancer and bladder cancer. However, the function of miRNA-320c in human glioma remained unclear. Here, we found that miRNA-320c was significantly down-regulated in glioma tissues and cell lines in contrast with normal brain tissues, being tightly related to clinical stage of glioma by qRT-PCR...
February 10, 2018: Brain Research Bulletin
Xuebao Xiang, Jiefu Huang, Wenfa Mo, Leiming Jiang, Wenguo Sun, Pengcheng Li
Recent advances have highlighted the important roles of long non-coding RNAs (lncRNAs) in a number of biological processes, including oncogenesis. However, the function of lncRNA cartilage injury-related (lncRNA-CIR) in bladder cancer progression remains elusive. A novel function for lncRNA-CIR in bladder cancer was identified in the present study. Reverse transcription quantitative polymerase chain reaction, viability, invasion assay and in vivo implantation were used to evaluate the role of lncRNA-CIR. It was identified that the expression of lncRNA-CIR was frequently upregulated in 52 cancerous tissues and selected bladder cancer cell lines...
March 2018: Oncology Letters
Ashfaque A Memon, Stephen C Gilliver, Michael Borre, Jan Sundquist, Kristina Sundquist, Ebba Nexo, Boe S Sorensen
The role of soluble human epidermal growth factor receptor (sHER3) in bladder cancer remains unclear. In the present study, an ELISA was developed for the quantification of sHER3 and its role was investigated in patients with bladder cancer (n=82) followed for 10 years. Furthermore, the effects of sHER3 on bladder cancer cell growth and migration were also investigated. The results demonstrated that plasma sHER3 levels were significantly higher in non-invasive tumours (Ta) compared with muscle-invasive tumours (T2-T4)...
February 2018: Oncology Letters
Heather J Chalfin, Max Kates, Emma E van der Toom, Stephanie Glavaris, James E Verdone, Noah M Hahn, Kenneth J Pienta, Trinity J Bivalacqua, Michael A Gorin
OBJECTIVE: To investigate circulating tumor cells (CTCs) as biomarkers of urothelial carcinoma (UC). The majority of this work to date has utilized the CellSearch test, which has limited sensitivity due to reliance on positive selection for the cell surface protein EpCAM. We used a novel selection-free method to enumerate and characterize CTCs across a range of UC stages. MATERIALS AND METHODS: Blood samples from 38 patients (9 controls, 8 non-muscle invasive bladder cancer [NMIBC], 12 muscle-invasive bladder cancer [MIBC] and 9 metastatic UC) were processed with the AccuCyte-CyteFinder system...
February 9, 2018: Urology
Alessandra Allione, Barbara Pardini, Clara Viberti, Marco Oderda, Marco Allasia, Paolo Gontero, Paolo Vineis, Carlotta Sacerdote, Giuseppe Matullo
BACKGROUND: Bladder cancer (BC) is one of the most aggressive malignancies of the urinary tract, with the highest lifetime treatment costs per patient of all cancers, due to the high rate of recurrences requiring continuous surveillance. An early diagnosis is essential to improve survival of patients with BC. Noninvasive and sensitive molecular biomarkers are needed to improve current strategies for the detection and monitoring of BC. Previous studies suggested that elevated DNA damage levels and suboptimal nucleotide excision DNA repair (NER) may be associated with BC...
February 6, 2018: Urologic Oncology
Rashid K Sayyid, Abdallah K Sayyid, Zachary Klaassen, Karen Hersey, Hanan Goldberg, Nathan Perlis, Ardalanejaz Ahmad, Ricardo Leao, Thenappan Chandrasekar, Kamel Fadaak, Rabii Madi, Martha K Terris, Antonio Finelli, Robert J Hamilton, Girish S Kulkarni, Alexandre R Zlotta, Neil E Fleshner
INTRODUCTION: Urinary biomarkers are being developed to detect bladder cancer recurrence/progression in patients with non-muscle invasive bladder cancer (NMIBC). We conducted a questionnaire-based study to determine what diagnostic accuracy and cost would such test(s) need for both patients and urologic oncologists to comfortably forgo surveillance cystoscopy in favor of these tests. METHODS: Surveys were administered to NMIBC patients at followup cystoscopy visit and to physician members of the Society of Urologic Oncology...
February 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Jacob C Kinskey, Yaping N Tu, Wei Lue Tong, John M Yavorski, George Blanck
We assessed pancreatic cancer, lymphocyte infiltrates with a computational genomics approach. We took advantage of tumor-specimen exome files available from the cancer genome atlas to mine T- and B-cell immune receptor recombinations, using highly efficient, scripted algorithms established in several previous reports. Surprisingly, the results indicated that pancreatic cancer exomes represent one of the highest level yields for immune receptor recombinations, significantly higher than two comparison cancers used in this study, head and neck and bladder cancer...
February 5, 2018: Cancer Microenvironment: Official Journal of the International Cancer Microenvironment Society
Cong Li, Xing Zeng, Zheng Liu, Fan Li, Kun Wang, Baisen Wu
BACKGROUND/AIMS: Emerging studies on brain-derived neurotrophic factor (BDNF) have shown that might be novel biomarkers and therapeutic targets for cancer. We explore the role of BDNF in the tumorigenesis of bladder cancer and the underlying molecular mechanism. METHODS: 368 patients with diagnosed bladder cancer and 352 healthy controls were enrolled to evaluate the association of BDNF and the miR-146b. Bioinformatics algorithm analysis and luciferase assay were performed to identify the target genes of miR-146b...
January 22, 2018: Cellular Physiology and Biochemistry
M Presler, A Wojtczyk-Miaskowska, B Schlichtholz, A Kaluzny, M Matuszewski, A Mika, T Sledzinski, J Swierczynski
Bladder cancer is a common disease and a significant cause of death worldwide. There is thus great interest in identifying a diagnostic and prognostic biomarker, as well as gaining an understanding of the molecular basis of bladder cancer. Stearoyl-CoA desaturase 1 gene (SCD1) is highly overexpressed in many human cancers. However, the expression of SCD1 has not yet been investigated in patients with bladder cancer. Here, we document that (a) the SCD1 is highly overexpressed in human bladder cancer; (b) high expression of SCD1 is more frequently observed in the late stage of disease and patients with lymph node metastasis; (c) bladder cancer patients with a higher SCD1 mRNA level have a poorer survival rate than those with normal SCD1 expression...
February 2, 2018: Molecular and Cellular Biochemistry
Seiji Asai, Noriyoshi Miura, Yuichiro Sawada, Terutaka Noda, Tadahiko Kikugawa, Nozomu Tanji, Takashi Saika
Combined gemcitabine and cisplatin (GC) treatment is a first line chemotherapy for bladder cancer. However, acquired resistance to GC has been a major problem. To address the mechanism of gemcitabine resistance, and to identify potential biomarkers or target proteins for its therapy, we aimed to identify candidate proteins associated with gemcitabine resistance using proteomic analysis. We established gemcitabine-resistant human bladder cancer cell lines (UMUC3GR and HT1376GR) from gemcitabine-sensitive human bladder cancer cell lines (UMUC3 and HT1376)...
January 2018: Oncology Letters
Chengdi Yang, Wenbo Yuan, Xiao Yang, Peng Li, Jingzi Wang, Jie Han, Jun Tao, Pengchao Li, Haiwei Yang, Qiang Lv, Wei Zhang
BACKGROUND: Circ-ITCH is a circRNA generated from several exons of itchy E3 ubiquitin protein ligase (ITCH) and tumor suppressor served as a sponge for certain miRNAs targeting their parental transcripts of ITCH. However, the role of circ-ITCH in bladder cancer (BCa) was not reported. In the present study, we investigated the role of circ-ITCH in BCa. METHODS: Quantitative real-time PCR was used to detect the expression of circ-ITCH and survival analysis was adopted to explore the association between circ-ITCH expression and the prognosis of BCa...
January 31, 2018: Molecular Cancer
Cinzia Antognelli, Vincenzo Nicola Talesa
Urological cancers include a spectrum of malignancies affecting organs of the reproductive and/or urinary systems, such as prostate, kidney, bladder, and testis. Despite improved primary prevention, detection and treatment, urological cancers are still characterized by an increasing incidence and mortality worldwide. While advances have been made towards understanding the molecular bases of these diseases, a complete understanding of the pathological mechanisms remains an unmet research goal that is essential for defining safer pharmacological therapies and prognostic factors, especially for the metastatic stage of these malignancies for which no effective therapies are currently being used...
January 31, 2018: International Journal of Molecular Sciences
Yongcan Xu, Xiang Yu, Chenchen Wei, Fengqi Nie, Mingde Huang, Ming Sun
BACKGROUND: Recently, the pesudogenes have emerged as critical regulators in human cancers tumorigenesis and progression, and been identified as a key revelation in post-genomic biology. However, the expression pattern, biological function and mechanisms responsible for these molecules in human gastric cancer (GC) are not fully understood. METHODS: In this study, we globally assessed the transcriptomic differences of pesudogenes in gastric cancer using publicly available microarray data...
January 27, 2018: Journal of Experimental & Clinical Cancer Research: CR
Kim E Van Kessel, Kirstin A van der Keur, Lars Dyrskjøt, Ferran Algaba, Naeromy Yc Welvaart, Willemien Beukers, Ulrika Segersten, Bastian Keck, Tobias Maurer, Tatjana Simic, Marcus Horstmann, Marc-Oliver Grimm, Gregers G Hermann, Karin Mogensen, Arndt Hartmann, Niels Harving, Astrid C Petersen, Jørgen B Jensen, Kerstin Junker, Joost L Boormans, Francisco X Real, Nuria Malats, Per-Uno Malmström, Torben F Ørntoft, Ellen C Zwarthoff
PURPOSE: The European Association of Urology (EAU) guidelines for non-muscle invasive bladder cancer (NMIBC) recommend risk stratification based on clinicopathological parameters. Our aim was to investigate the added value of biomarkers to improve risk stratification of NMIBC. EXPERIMENTAL DESIGN: We prospectively included 1239 patients in follow-up for NMIBC in six European countries. Fresh frozen tumor samples were analyzed for GATA2, TBX2, TBX3 and ZIC4 methylation and FGFR3, TERT, PIK3CA and RAS mutation status...
January 24, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Naoya Niwa, Kazuhiro Matsumoto, Hiroki Ide, Hirohiko Nagata, Mototsugu Oya
PURPOSE: To investigate the relationship between albumin-to-globulin ratio (AGR) and oncologic outcomes in patients with non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: We identified 364 patients with primary NMIBC who underwent transurethral surgery between 2000 and 2015. The association between pretreatment AGR and clinicopathologic variables, including oncologic outcomes, was statistically evaluated. RESULTS: One hundred twenty patients (33...
January 4, 2018: Clinical Genitourinary Cancer
Jaroslav Juracek, Barbora Peltanova, Jan Dolezel, Michal Fedorko, Dalibor Pacik, Lenka Radova, Petra Vesela, Marek Svoboda, Ondrej Slaby, Michal Stanik
Urinary microRNAs (miRNAs) are emerging as clinically useful tool for early and non-invasive detection of various types of cancer including bladder cancer (BCA). In this study, 205 patients with BCA and 99 healthy controls were prospectively enrolled. Expression profiles of urinary miRNAs were obtained using Affymetrix miRNA microarrays (2578 miRNAs) and candidate miRNAs further validated in independent cohorts using qRT-PCR. Whole-genome profiling identified 76 miRNAs with significantly different concentrations in urine of BCA compared to controls (P < 0...
January 24, 2018: Journal of Cellular and Molecular Medicine
Oner Sanli, Yair Lotan
Management of high risk non-muscle invasive bladder cancer (NMIBC) is challenging. It is vital to detect recurrences early and predict which tumors are likely to progress. Areas covered: This manuscript reviews the current approaches available for detection and surveillance of high risk NMIBCs. A literature review was utilized to evaluate risk factors for recurrence and progression as well as evaluating approaches including pathological aspects of NMIBC, molecular subtyping, methods for tumor visualization, urine cytology, urinary molecular markers, molecular tissue markers as well as the scoring systems and nomograms...
January 23, 2018: Expert Review of Anticancer Therapy
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang
Urothelial bladder cancer (UBC) is one of the most common lethal cancer worldwide and the 5-year survival rate has not improved significantly with current treatment protocols during the last decade. Intravesical immunotherapy with Bacillus Calmette-Guérin is currently the standard care for non-muscle invasive UBC. Recently, a subset of patients with locally advanced or metastatic UBC have responded to checkpoint blockade immunotherapy against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1) or the cytotoxic T-lymphocyte antigen 4 that releases the inhibition of T cells, the remarkable clinical efficacy on UBC has brought total five checkpoint inhibitors approved by the FDA in the last 2 years, and this is revolutionizing treatment of advanced UBC...
January 23, 2018: Oncogenesis
Zhen Li, Kang-Er Wang, Xie-Lai Zhou, Jin Zhou, Chun-Hua Ye
BACKGROUND The aim of this study was to investigate the expression of long non-coding RNAs (lncRNA) cancer susceptibility candidate 2a (CASC2a) in patients with urothelial carcinoma of the bladder (UCB) and its predictive value in the recurrence of UCB after radical cystectomy (RC). MATERIAL AND METHODS Tumor and paired adjacent normal tissues were obtained from 112 patients with UCB who underwent RC in our hospital from March 2010 to March 2012. The expression of CASC2a was evaluated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH)...
January 23, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"